Objective: It is generally agreed that when the blood contact surfaces of a cardiopulmonary bypass circuit are treated with a layer of heparin molecules the activation of the humoral pathways is attenuated. However, there is still debate as to whether heparin-bonded circuits reduce thrombin generation. This study aims to examine the effects of immobilized heparin on cell activation and thrombin generation in a novel, well controlled model of cardiopulmonary bypass. Methods: The model used consisted of a heparin-bonded and a non-bonded cardiopulmonary bypass circuit perfused in tandem with the same unit of fresh heparinized (3.3 U/ml) human blood for a period of 6 h. Samples were taken for analysis from the bag just prior to perfusion and at 30, 60, 120 and 360 min of perfusion. Whole blood was used to analyse platelet and white blood cell count, haematocrit and activated coagulation time. Plasma samples were prepared for batch analysis of the cell activation markers p-selectin, elastase and interleukin-8, and the thrombin generation markers thrombin-antithrombin and prothrombin fragment F1+2. A sample of tubing was taken from each circuit at the end of the perfusion and prepared for visualization by scanning electron microscopy. Results: Platelet counts were significantly reduced in the non-bonded circuits compared with the heparin-bonded circuits at 30 (22 versus  200×10 9 /L PB0.01), 60 (26 versus 193×10 9 /L P B0.01) and 120 min (28 versus 193 × 10 9 /L PB 0.01) as were white blood cell counts at 30(1.5 versus 2.7 × 10 9 /L P B0.01), 60 (0.9 versus 2.4×10 9 /L PB 0.01), 120 (0.9 versus 1.8×10 9 /L PB 0.01) and 360 min (0.4 versus 0.9 × 10 9 /L P B0.05). The concentration of p-selectin was found to be significantly higher in the non-bonded circuits than in the heparin-bonded circuits at 30 (37 versus 29 ng/ml PB 0.01), 60 (37 versus 28 ng/ml P B 0.01), 120 (42 versus 27 ng/ml PB0.01) and at 360 min (72 versus 46 ng/ml PB 0.01). Elastase was elevated in the non-bonded circuits at 30 (570 versus 145 vg/l PB0.01), 60 (646 versus 278 vg/l P B0.01) and 120 min (613 versus 403 vg/l P B0.05) and interleukin-8 at 120 (705 versus 520 pg/ml P B0.05) and 360 min (11 326 versus 9910 pg/ml P B 0.05). A similar picture was found for the thrombin generation markers. Thrombin-antithrombin complexes were raised in the non-bonded circuits compared with heparin-bonded circuits at 60 (24 versus 13 vg/l PB0.05) and 120 min (46 versus 17 vg/l PB 0.05) as was prothrombin fragment F1 + 2 at 30 (1.1 versus 0.7 nmol/l P B0.01), 60 (1.3 versus 0.7 nmol/l PB0.01), 120 (1.8 versus 0.9 nmol/l PB0.01) and 360 min (15.0 versus 13.6 nmol/l PB0.05). Scanning electron microscopy revealed a greater amount of adherent material on the non-bonded surface relative to the heparin-bonded surface. Conclusions: In a cardiopulmonary bypass circuit perfused with human blood the activation of platelets and white blood cells has been seen to be significantly reduced in the presence of a heparin-bonded surface. Thrombin generation due to contact activation of the intrinsic coagulation pathway is also reduced. © 1997 Elsevier Science B.V.
Introduction
Cardiopulmonary bypass (CPB) induces a whole body inflammatory response. The two main stimuli of this activation are surgical trauma (releasing tissue factor and causing induction of the extrinsic pathway) and the contact of blood with the non-endothelial surfaces of the bypass circuit (stimulating intrinsic pathway activation). An underlying level of coagulation has been demonstrated to take place during CPB despite the use of 4.1 IU/ml heparin [19] .
The reactions initiated when blood comes into contact with a foreign surface have been shown to be significantly reduced when such surfaces have been pretreated with a layer of heparin molecules [25, 26, [30] [31] [32] 35, 45, 46] . Cardiopulmonary bypass (CPB) circuits with heparin-bonded (HB) surfaces became commercially available at the beginning of this decade and most work to date has investigated two types of heparin bonding; Carmeda (Medtronic, Kerkrade, Netherlands) and Duraflo II (Irvine, CA, USA). HB surfaces have been found to behave in a manner analogous to the endothelial surface itself [1] . Both the Carmeda [4, 5, 14, 16, 37, 44, 47, 49] and the Duraflo II [3, 20, 29, 33, 34, 43, 50, 51] circuits showed clinical benefits although the findings for the Carmeda surface have tended to be the more impressive. A recent prospective randomized trial confirmed this trend [29] . However, the efficacy of immobilized heparin in reducing the activation of humoral pathways during CPB has been questioned by others, particularly in relation to thrombin generation [18] .
In part, this disagreement has stemmed from poor experimental design or the use of small sample sizes which can cause differences which actually exist not to be found (type II errors). Due to inconsistencies in the literature with regard to the efficacy of HB surfaces, a novel in vitro setup was designed. By perfusing two circuits simultaneously with the same (divided) unit of fresh heparinized human blood the probability of type II errors during comparisons is reduced. The current in vitro study tested the hypothesis that [1] Carmeda HB circuits reduce thrombin generation and [2] these circuits maintain biocompatibility for up to 6 h when compared with matched control non-bonded (NB) circuits.
Methods

Blood collection
Following approval by the local ethics committee and informed consent, blood (450 ml) was drawn from healthy adult volunteers into 1 L bags (Baxter Healthcare, Norfolk, UK) to which heparin (Leo Laboratories, UK) had previously been added to produce 3.3 U/ml. Within 30 min of collection, the blood was brought to the laboratory where it was diluted to approximately bypass haematocrit ( 20%) by the careful addition of 150 ml each of Hartmann's solution (Baxter Healthcare) and gelofusin (B. Braun Medical, Emmenbruke, Switzerland). A sample was taken from the bag (final volume 750 ml) prior to perfusion to obtain baseline activated coagulation time (ACT, HemoTec, Medtronic, CA) and full blood count values (into 1.6 mg/ml EDTA).
Simulated cardiopulmonary bypass
Circuits, 20, were used in this study, ten of which were Carmeda HB and ten NB. The two circuit types were perfused simultaneously in each experiment using an equivalently divided unit of diluted blood. The circuit consisted of a Minimax (Medtronic) paediatric membrane oxygenator and a Biopump (Medtronic) centrifugal pump connected by PVC tubing. The volume of each circuit was approximately 300 ml, with an inner surface area of around 1 m 2 . The circuits were perfused with the blood according to the manufacturers' instructions. Flow was adjusted to maintain 1 L/min over a 6 h perfusion period. Temperature was kept at 28°C for 4 h and then increased to 37°C for the rest of the perfusion to mimic a rewarming period. Physiological pH was maintained by flowing a calibrated gas mixture of 5% carbon dioxide, 12% oxygen and 83% nitrogen through the oxygenator at 1 ml/min.
Blood samples, 15.6 ml, were simultaneously drawn from the paired circuits at 30, 60, 120 and 360 min. Where blood was removed it was replaced with an equivalent volume of Hartmann's solution in order to prevent creation of a negative pressure in the system. This amounted to 21% of the circuit volume in total causing a fall in haematocrit from 0.26 to 0.23 at the end of the experiment. Whole blood was used for the measurement of ACT and heparinase ACT (Medtronic HemoTec) as well as platelet and white blood cell (WBC) counts. The heparinase ACT channel contained a purified bacterial heparinase which destroyed the heparin present in the sample producing a clotting time indicative of the respective baseline unheparinized clotting time. The rest of the blood was collected into citrate (0.3 w/v, 1:9) and centrifuged at 1500 × g for 10 min at 4°C and plasma was aliquoted into 0.5 ml samples which were stored immediately in a −80°C freezer for subsequent batch analyses.
Commercial enzyme immunoassay kits were used to measure the plasma levels of soluble p-selectin, a sensitive marker of platelet activation (R&D Systems, Oxon, UK), leucocyte elastase as a marker of leucocyte activation (E. Merck, Darmstadt, Germany), thrombin-antithrombin complex (TAT) and prothrombin fragment F1+ 2, specific markers of thrombin formation (Behring, Marburg, Germany) and interleukin-8 (IL-8), a neutrophil chemoattractant (R&D systems).
Haemoglobin concentration was measured spectrophotometrically by the method of Harboe [21] with reduced volumes. 0.1 ml of plasma was added to 1.0 ml of 0.01% Na 2 CO 3 and the optical density was measured at 415, 380 and 450 nm. Use of an equation including a correction formula yielded the concentration of haemoglobin in mg/100 ml;
An E value of 8.6 was used, as calculated from the data of Donaldson et al [13] . At the conclusion of the perfusion period, samples of tubing were taken from both circuits and rinsed with Hartmann's solution to remove any excess red blood cells. The samples were then fixed in 2% glutaraldehyde in phosphate buffered saline for 15 min before being dehydrated in ascending concentrations of ethanol up to absolute ethanol. They were subsequently air-dried in a desiccator and sputter coated with gold for viewing on a Jeol JSM T20 scanning electron microscope (Tokyo, Japan) operating at 20 kV.
Statistics
Sample size calculations for detecting a difference between two medians were carried out using expected values from previous work similar to this [39, 45] . It was established that a sample size of at least ten for each group would be sufficient to demonstrate differences with a power value of 0.85 and a significance of 0.05.
Friedman analysis of variance was applied to detect differences between the two circuit types. Analysis was subsequently carried out by means of Wilcoxon matched pairs tests to detect where the differences existed between the two circuits.
Results
Platelets and leucocytes
In the NB circuits the platelet counts had decreased to The concentrations of the markers used to measure platelet and leucocyte activation, p-selectin and elastase, were found to be raised in the NB circuits in comparison to the bonded circuits. P-selectin was higher at 30 (37. Fig. 2b] ). Il-8 was raised from baseline levels (15.3(6.4-25.5) pg/ml) from 60 min in both HB (99(6-196) pg/ml PB 0.05) and NB (86 ) pg/ml P B0.05), markedly so at 360 min (HB 9910(1628-10910) pg/ml, NB 11325(8329-12448) pg/ml PB 0.005), and was found to be significantly higher in the NB circuits compared to the HB circuits at 120 (705(244-1491) versus 520(18-642) pg/ml PB 0.01) and 360 min (PB 0.05) [Fig. 2c]) . 
Thrombin generation
Plasma haemoglobin rose at the final timepoint from a baseline level of 0.119 -0.298 mg/100 ml in the HB circuits and 0.432 mg/100 ml in the NB circuits. A significant difference was not established probably due to the variability in the measurements between experiments.
Baseline ACTs were above 400 s, whilst the heparinase ACTs were within normal limits (mean 9 S.D.; 148917). Significant between sample variability was seen in ACT measurements whereas the heparinase ACTs remained stable except at 360 min in NB circuits (Fig. 3) . No macroscopic clots were visible in the oxygenators of either circuit type. Scanning electron microscopy revealed that the HB tubing surfaces allowed less adherence of cellular material than the NB surfaces which was exemplified by fibrin formation on the latter (Fig. 4) .
TATs concentration in the baseline sample was notably high (48.3(6.2-84) mg/l). Significantly higher levels were measured in the NB circuits as compared with the HB circuits at 60 (24(12-31.8) versus 12.7(8.1-14) mg/l PB 0.01) and 120 min (46(26.8-58.1) versus 17.4(11.7-19.7) mg/l PB 0.01 [ Fig. 5a]) . F1+ 2 at baseline was also high (4.5(0.5-5.9) nmol/l) but once perfusion commenced, a significantly higher concentration of the marker was detected in the NB circuits at 30 (1.2(0.9-1.3) versus 0.7(0.6-0.8) nmol/l P B0.01), 60 (1.3(1-0.9) versus 0.7(0.6-0.9) nmol/l P B 0.01), 120 (1.9(1.6-1.9) versus 1.2(0.7-1) nmol/l P B 0.01) and 360 min (15.2(11.5-16.5) versus 13.6(1.8-15.7) nmol/l PB0.05 [ Fig. 5b] ).
Discussion
In the present study, an in vitro model of CPB was used to compare HB circuits with NB circuits in terms of blood cell activation and thrombin generation. The use of matched blood perfusate allowed comparisons to be made between circuits with a high degree of confi- reduce the activation of platelets and plasma coagulation enzymes, properties which ultimately lead to a reduction in thrombin generation via the contact activation pathway.
Platelets and leucocytes
As the perfusion system used in this work was a closed one, changes in blood cell count are most probably a result of interaction with the circuit either by adherence to the surface or damage by shear stress. The cell reduction in the NB circuits was of a greater magnitude to that reported in other simulated extracorporeal perfusions [9, 10] , possibly due to a lower level of heparin. The slight increase in cell numbers over time is probably due to a re-release from the surface. this has been noted by others in the past [53] . On adhering to the surface cell activation would be expected to occur. In the case of platelets, p-selectin, found in the h-granules, provided an indication as to their state of activation. It moves to the cell surface in response to inflammatory or thrombotic agents [38] and concentrations of soluble p-selectin reflect this reaction as well as indicating h-granule release. P-selectin plays a major role in the interaction of activated platelets to monocytes [15] . The superior maintenance of platelet numbers in the HB circuits in conjunction with lower levels of p-selectin in plasma suggests that platelet activation was reduced with heparin-bonding. It is of note that this effect became significant as early as 30 min of perfusion. Thus demonstrating an apparent synergistic cell protective effect of surface-bound heparin and fluid phase heparin.
Leucocytes also have a strong tendency to stick to artificial surfaces which is influenced to a great extent by substances released by platelets [36] . Because the leucocyte counts remained significantly higher in the HB circuits it is probable that there was less adhesion to this surface. On adhesion, substances are released, including the protease elastase which is a constituent of the primary granules of leucocytes [42] which also acts to enhance platelet activation [15] . It has been shown to be released concomitant with activation of plasma kallikrein [9] which is involved in contact activation. The neutrophil chemotactic factor IL-8 is also known to be derived from leucocytes and in a closed system of extracorporeal circulation this is probably the sole source [28] . There was a time dependent rise in both elastase and IL-8 but greater quantities of these substances were released from the leucocytes in the NB circuits compared with the HB circuits, demonstrating a suppression of the release reaction due to immobilized heparin.
Research has shown that the adsorption of certain proteins to the surface favours cell adherence more than others [1, 9, 17, 26, 27, 31, 32, 48] . This initial surface dence for identifying 'real' differences and reducing type II errors which has been of concern in several previous papers. The paired nature of the model meant that the NB circuit acted as a control, alleviating the necessity for non-circulating controls.
The contact pathway of coagulation is activated by the perfusion of blood through an artificial apparatus [52] . Early work with the Carmeda surface showed that although the thrombin binding capacity of surface heparin was high it did not inhibit thrombin activity to the same extent as fluid-phase heparin [32] . Therefore it is important to rationalise the reasoning behind utilizing heparin-bonded circuits. It is inaccurate to say that surface-bound heparin acts as an anticoagulant and that the surface is non-thrombogenic as is sometimes suggested. However, it has been demonstrated that this surface has thromboresistant properties and is more compatible with the blood [26, 31, 32] . Such surfaces layer of proteins has been termed the 'conditioning layer'. One of the main determining factors for stimulation of contact activation and cell adherence is the initial adsorption of fibrinogen. Studies have shown that the protein adsorbate on heparinized surfaces exposed to plasma contains little fibrinogen [31] . It can be expected that this is also true of whole blood since the rheological effect of red blood cells has minimal effect on plasma proteins [6] . As a result, the propensity for platelets and leucocytes to adhere to the surface and become activated is reduced [8, 42] . This has been clearly demonstrated in the current experiments.
Thrombin generation
Procoagulants released from platelets can stimulate the intrinsic pathway of coagulation involving the contact proteins factor XII, factor XI, high molecular weight kininogen and prekallikrein [54] therefore reducing the release reaction also curtails thrombin generation. With standard, NB circuits, subclinical coagulopathy has been reported to occur even when full heparinization is employed [19] . It has previously been suggested that HB CPB circuits attenuate this response [41] . This view was upheld in the current experiments, at variance with the observations of Gorman et al [18] , but from which type II error was strongly suggestive.
The prolongation in the ACT is consistent with the phenomenon of consumptive coagulopathy. As has been established previously [2, 11] , the ACT is not an ideal test for monitoring coagulation during CPB as it is affected by hypothermia, haemodilution and other factors. In addition, there is a large degree of variability between subjects [7] which was observed in the current experiments. Alternative strategies of heparin administration and neutralization that take into account this variability have been advocated [22] . The most widely used protocols are largely empirical in nature and there is disagreement as to the optimal level of anticoagulation clinically. In order to prevent any coagulation occurring, heparin levels which result in bleeding problems [12, 19] and platelet dysfunction [23, 24, 40] would need to be administered. This work has demonstrated that this dilemma is alleviated with the use of HB circuits due to the suppression of coagulation compared with the non-bonded circuits even with full heparinization.
Scanning electron microscopy clearly revealed cell clusters and fibrin strands on the surface of the NB tubing at 360 min indicating an advanced stage of coagulation. The surfaces of the HB circuits generally appeared to remain free from adherent material throughout the perfusion period, showing that the typical reactions that occur when blood contacts a foreign surface are attenuated.
Plasma levels of TATs provide evidence of the state of thrombin generation since antithrombin only reacts with activated thrombin. Due to the fact that these complexes have a short half-life ( 10 min) they act as an indicator of the current state of activation. In the short time between blood collection and use, the TATs levels demonstrated a transient rise in activation in the bag, implying a damaging effect on static heparinized blood. This observation has implications for blood storage which are beyond the scope of the present discussion. TATs were subsequently found to be significantly less in the HB circuits compared with the NB circuits up to 120 min of perfusion. This is a strong indication that there was less activation of the coagulation cascade up to 120 min when the surfaces were HB. At 360 min, TATs were found to be elevated in both circuit types with no significant difference found. It is unsure as to whether this effect was due to the length of the perfusion or as a result of rewarming. The amount of F1+ 2 formed in blood is equivalent to the amount of thrombin formed. As with TATs, there was activation of coagulation in the blood prior to circulation. Throughout the perfusion period, the HB circuits showed less formation of thrombin than the NB circuits. This adds further credence to the notion that there is reduced activation of the coagulation cascade with HB surfaces.
The benefit of employing a closed in vitro system is that a specific component of the clinical situation can be evaluated in isolation. For the same reason there are limitations with regard to applying the information obtained to the patient. The authors also recognise that there is ambiguity with regard to the measurements at the final timepoint due to the fact that both time and rewarming effects were present. In vitro rewarming is not buffered as it is by the patient clinically and hence is more rapid. This would have been likely to have an effect on the concentration of the various markers. However, these experiments do allow conclusions to be made with regard to the efficacy of immobilized heparin in reducing the adverse reactions produced when human blood is circulated through a CPB circuit.
HB CPB circuits demonstrate a significant attenuation of the reactions which are known to be induced by the contact of blood with a foreign surface and lead to the generation of thrombin. From the observations made in this work it can be concluded that there is a practical advantage in using Carmeda HB CPB circuits in terms of cell preservation and reduced activation of the contact system of coagulation for the duration of a typical CPB operation.
By the simultaneous perfusion of HB and NB circuits, this study would appear to be the first controlled study to demonstrate reduced thrombin formation through heparin bonding of an extracorporeal circuit. It is hoped that our observations will help to reach a better understanding of the behaviour of HB circuits.
